- Patient outcomes were defined by protocol (n=107) or for-cause (n=44) kidney biopsy.
- Median time to biopsy and Tutivia risk score was 57 days, and a high risk score predicting acute rejection as early as 6 days post-transplant.
-
80% of clinically indicated biopsies were performed within the first sixty days.
- 69% of these had acute rejection by histopathology.
- 83% of early biopsies with pathologic acute rejection had a high Tutivia risk score.
Tutivia ™
Tutivia™ is a blood-based transcriptomic RNA signature that utilizes a proprietary algorithm to create an acute rejection risk assessment score in kidney transplant patients. For more information about Tutivia™ and the next-gen sequencing technology visit our website at vericidx.com, then click on the technology section at the top, then click on RNA signatures.
PTRA ™
PTRA™ (Pre-Transplant Risk Assessment) , formerly known as Clarava, is the first pre-transplant prognostic test to assess a patient's immune phenotype for the probable risk of early kidney graft rejection. The validation study represents a significant demonstration of PTRA™ as a predictive test capable of informing a clear, actionable response from clinicians. Verici Dx has licensed PTRA to Thermo Fisher (One Lambda) for commercial availability sometime in 2024.